GLPBio

BTK

BTK (Bruton's tyrosine kinase) binds PIP3 and phosphorylates phospholipase C, plays a crucial role in B cell maturation as well as mast cell activation.

Products Related to BTK(73)

  • GC11230 structure
    GC11230RN486
    CAS: 1242156-23-5
    Purity: >99.50%

    Btk inhibitor,potent and selective

  • GC11063 structure
    GC11063BMX-IN-1
    CAS: 1431525-23-3
    Purity: >98.50%

    A selective BMX and BTK inhibitor

  • GC11995 structure
    GC11995GDC-0834
    CAS: 1133432-50-4
    Purity: >99.00%

    GDC-0834 is the S-enantiomer of GDC-0834.

  • GC13219 structure
    GC13219ONO-4059
    CAS: 1351635-67-0
    Purity: >99.50%

    ONO-4059 is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor.

  • GC13365 structure
    GC13365CGI-1746
    CAS: 910232-84-7
    Purity: >98.00%

    A potent, selective BTK inhibitor

  • GC13439 structure
    GC13439CNX-774
    CAS: 1202759-32-7
    Purity: >99.00%

    BTK inhibitor, orally active, irreversible and selective

  • GC13562 structure
    GC13562AVL-292
    CAS: 1202757-89-8
    Purity: >98.00%

    A covalent BTK inhibitor

  • GC13812 structure
    GC13812PCI-32765 (Ibrutinib)
    CAS: 936563-96-1
    Purity: >99.50%

    PCI-32765 (Ibrutinib) is an irreversible selective inhibitor of Bruton s tyrosine kinase (BTK) that selectively targets its kinase domain and modulates BTK downstream signaling by reducing its phosphorylating capacity with IC50 of 0.5 nM in cell-free assays.

  • GC14857 structure
    GC14857LFM-A13
    CAS: 244240-24-2
    Purity: >99.50%

    BTK-specific tyrosine kinase inhibitor

  • GC15453 structure
    GC15453ACP-196
    CAS: 1420477-60-6
    Purity: >99.50%

    ACP-196 (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. ACP-196 binds covalently to Cys481 in the ATP-binding pocket of BTK. ACP-196 demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

  • GC19162 structure
    GC19162GDC-0853
    CAS: 1434048-34-6
    Purity: >99.50%

    GDC-0853 (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. GDC-0853 has the potential for rheumatoid arthritis and systemic lupus erythematosus research.

  • GC19333 structure
    GC19333BTK IN-1
    CAS: 1270014-40-8
    Purity: >98.50%

    BTK IN-1 is a potent BTK inhibitor, with an IC50 of <100 nM.

  • GC30155 structure
    GC30155PCI-33380
    CAS: 1022899-36-0
    Purity: >98%

    PCI-33380 is an irreversible and selective Bruton's Tyrosine Kinase (BTK) inhibitor (fluorescent probe).

  • GC31339 structure
    GC31339PRN1008
    CAS: 1575596-29-0
    Purity: >98.00%

    PRN1008 (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton's Tyrosine Kinase (BTK), with an IC50 of 1.3 nM.

  • GC31679 structure
    GC31679ARQ 531
    CAS: 2095393-15-8
    Purity: >99.00%

    ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase (BTK), with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.

  • GC31713 structure
    GC31713BMS-986142
    CAS: 1643368-58-4
    Purity: >99.50%

    A BTK inhibitor

  • GC31760 structure
    GC31760BMS-935177
    CAS: 1231889-53-4
    Purity: >99.00%

    BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC50 of 3 nM.

  • GC32007 structure
    GC32007Btk inhibitor 2
    CAS: 1558036-85-3
    Purity: >99.50%

    Btk inhibitor 2 (BGB-3111 analog) is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.

  • GC32844 structure
    GC32844BMS-986195
    CAS: 1912445-55-6
    Purity: >99.50%

    BMS-986195 (BMS-986195) is a highly potent, selective covalent, irreversible inhibitor of Bruton's tyrosine kinase (BTK), with an IC50 of 0.1 nM.

  • GC33064 structure
    GC33064CG-806 (Luxeptinib)
    CAS: 1616428-23-9
    Purity: >99.00%

    CG-806 (Luxeptinib) (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. CG-806 (Luxeptinib) induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells.

  • GC33821 structure
    GC33821Tirabrutinib (ONO-4059)
    CAS: 1351636-18-4
    Purity: >99.50%

    Tirabrutinib (ONO-4059) (ONO-4059) is an orally active Bruton's Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC50 of 6.8 nM.

  • GC34062 structure
    GC34062Evobrutinib (M2951)
    CAS: 1415823-73-2
    Purity: >98.00%

    Evobrutinib (M2951) is an orally active Bruton tyrosine kinase (BTK) inhibitor with an IC 50 of 8.9nM.

  • GC34069 structure
    GC34069(±)-Zanubrutinib ((±)-BGB-3111)
    CAS: 1633350-06-7
    Purity: >99.50%

    (±)-Zanubrutinib ((±)-BGB-3111) ((±)-BGB-3111) is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.

  • GC34075 structure
    GC34075Zanubrutinib (BGB-3111)
    CAS: 1691249-45-2
    Purity: >99.00%

    Zanubrutinib (BGB-3111) (BGB-3111) is a selective Bruton tyrosine kinase (Btk) inhibitor.